Growth Hormone Secretagogues

A synthetic analog of growth hormone-releasing hormone (GHRH) designed for a longer duration of action, studied for stimulating the body's own GH release.

A growth-hormone-releasing peptide that stimulates GH via the ghrelin receptor, also increasing appetite.

An early growth-hormone-releasing peptide acting on the ghrelin receptor, notable for pronounced appetite stimulation.

A potent growth-hormone-releasing peptide acting on the ghrelin receptor, with additional research interest in cardiac tissue.

A modified, long-acting analog of insulin-like growth factor 1 used as a research chemical for its anabolic signaling — with meaningful safety concerns.

A selective ghrelin-receptor agonist studied as a growth hormone secretagogue — it prompts the pituitary to release the body's own growth hormone.

An orally active ghrelin-receptor agonist (growth hormone secretagogue) that raises GH and IGF-1; a small molecule rather than a peptide, with some human study data.

A GHRH analog (the 1-29 fragment) with a history of approved diagnostic/clinical use, now commonly compounded as a growth hormone secretagogue.

A stabilized growth-hormone-releasing hormone (GHRH) analog that stimulates the body's own GH output, FDA-approved for HIV-associated visceral fat accumulation.